(NP (NP (NP A/DT mechanism/NN) (PP for/IN (NP (NP the/DT antiinflammatory/JJ effects/NNS) (PP of/IN (NP corticosteroids/NNS)))) :/:) (S (NP-SBJ the/DT glucocorticoid/NN receptor/NN) (VP regulates/VBZ (NP-COOD (NP (NP leukocyte/NN adhesion/NN) (PP to/TO (NP endothelial/JJ cells/NNS))) and/CC (NP (NP expression/NN) (PP of/IN (NP-COOD (NP endothelial-leukocyte/JJ adhesion/NN molecule/NN 1/CD) and/CC (NP intercellular/JJ adhesion/NN molecule/NN 1/CD)))))) ./.))
(S (NP-SBJ Corticosteroids/NNS) (VP are/VBP (NP-PRD the/DT preeminent/JJ antiinflammatory/JJ agents/NNS) (SBAR although/IN (S (NP-SBJ-9 (NP the/DT molecular/JJ mechanisms/NNS) (SBAR (WHNP-10 that/WDT) (S (NP-SBJ *T*-10/-NONE-) (VP impart/VBP (NP their/PRP$ efficacy/NN))))) (VP have/VBP not/RB (VP been/VBN (VP defined/VBN (NP *-9/-NONE-))))))) ./.)
(S (NP-SBJ-11 The/DT endothelium/NN) (VP plays/VBZ (NP a/DT critical/JJ role/NN) (PP in/IN (NP inflammation/NN)) (PP by/IN (S (NP-SBJ-12 *-11/-NONE-) (VP directing/VBG (NP circulating/VBG leukocytes/NNS) (PP into/IN (NP extravascular/JJ tissues/NNS)) (PP by/IN (S (NP-SBJ *-12/-NONE-) (VP expressing/VBG (NP (NP (NP adhesive/JJ molecules/NNS) (PP for/IN (NP leukocytes/NNS))) (PRN -LCB-/-LRB- (PP e.g./FW ,/, (NP-COOD (NP (NP endothelial-leukocyte/JJ adhesion/NN molecule/NN 1/CD) (PRN -LRB-/-LRB- (NP ELAM-1/NN) -RRB-/-RRB-)) and/CC (NP (NP intercellular/JJ adhesion/NN molecule/NN 1/CD) (PRN -LRB-/-LRB- (NP ICAM-1/NN) -RRB-/-RRB-)))) -RCB-/-RRB-))))))))) ./.)
(S (NP-SBJ We/PRP) (ADVP therefore/RB) (VP determined/VBD (SBAR whether/IN (S (NP-SBJ-13 corticosteroids/NNS) (VP suppress/VBP (NP inflammation/NN) (PP by/IN (S (NP-SBJ *-13/-NONE-) (VP inhibiting/VBG (NP (NP endothelial/JJ expression/NN) (PP of/IN (NP (NP (NP adhesion/NN molecules/NNS) (PP for/IN (NP neutrophils/NNS))) (PRN -LRB-/-LRB- (NP polymorphonuclear/JJ leukocytes/NNS) -RRB-/-RRB-))))))))))) ./.)
(S (NP-SBJ (NP Preincubation/NN) (PP of/IN (NP endothelial/JJ cells/NNS)) (PP with/IN (NP (NP endotoxin/NN) (PRN -LCB-/-LRB- (FRAG (NP (NP lipopolysaccharide/NN) (PRN -LRB-/-LRB- (NP LPS/NN) -RRB-/-RRB-)) ,/, (NP 1/CD microgram\/ml/NN)) -RCB-/-RRB-)))) (VP led/VBD (PP to/TO (NP (NP (NP a/DT (ADJP 4-fold/JJ) increase/NN) (PP in/IN (NP (NP subsequent/JJ adherence/NN) (PP of/IN (NP (NP polymorphonuclear/JJ leukocytes/NNS) (PRN -LRB-/-LRB- (S-COOD (S (NP-SBJ P/NN) (VP &lt;/VBG (NP 0.0001/CD))) ,/, (S (NP-SBJ n/NN) (VP =/JJ (NP-PRD 10/CD)))) -RRB-/-RRB-))) (PP to/TO (NP endothelial/JJ cells/NNS))))) ,/, (NP (NP an/DT increase/NN) (SBAR (WHNP-14 that/WDT) (S (NP-SBJ-15 *T*-14/-NONE-) (VP was/VBD (ADVP markedly/RB) (VP attenuated/VBN (NP *-15/-NONE-) (SBAR-TMP (WHADVP-16 when/WRB) (S (NP-SBJ-17 endothelial/JJ cells/NNS) (VP were/VBD (VP treated/VBN (NP *-17/-NONE-) (PP with/IN (NP (NP dexamethasone/NN) (PRN -LRB-/-LRB- (S-COOD (S (NP-SBJ IC50/NN) (VP &lt;/VBG (NP 1/CD nM/NN))) ,/, (S (NP-SBJ P/NN) (VP &lt;/VBG (NP 0.0001/CD))) ,/, (S (NP-SBJ n/NN) (VP =/VBG (NP-PRD-COOD (NP 6/CD) or/CC (NP 7/CD))))) -RRB-/-RRB-))) (PP-TMP during/IN (NP (NP preincubation/NN) (PP with/IN (NP LPS/NN)))) (ADVP *T*-16/-NONE-))))))))))))) ./.)
(S (ADVP Moreover/RB) ,/, (NP-SBJ-COOD (NP (NP the/DT steroid/NN receptor/NN agonist/NN cortisol/NN) (PRN -LRB-/-LRB- (FRAG (NP 10/CD microM/NN)) -RRB-/-RRB-)) ,/, (CONJP but/CC not/RB) (NP (NP its/PRP$ inactive/JJ metabolite/NN tetrahydrocortisol/NN) (PRN -LRB-/-LRB- (FRAG (NP 10/CD microM/NN)) -RRB-/-RRB-)) ,/,) (VP diminished/VBD (NP LPS-induced/JJ endothelial/JJ cell/NN adhesiveness/NN)) ./.)
(S (NP-SBJ-18 Further/JJ evidence/NN (SBAR that/IN (S (NP-SBJ-19 (NP the/DT action/NN) (PP of/IN (NP dexamethasone/NN))) (VP was/VBD (VP mediated/VBN (NP *-19/-NONE-) (PP through/IN (NP (NP ligation/NN) (PP of/IN (NP (NP corticosteroid/NN receptors/NNS) (PRN -LCB-/-LRB- (NP (NP human/JJ glucocorticoid/NN receptors/NNS) (PRN -LRB-/-LRB- (NP hGRs/NNS) -RRB-/-RRB-)) -RCB-/-RRB-)))))))))) (VP was/VBD (VP provided/VBN (NP *-18/-NONE-) (PP by/IN (NP-LGS (NP experiments/NNS) (VP utilizing/VBG (NP the/DT steroid/NN antagonist/NN RU-486/NN)))))) ./.)
(S (NP-SBJ (NP RU-486/NN) (PRN -LRB-/-LRB- (FRAG (NP 10/CD microM/NN)) -RRB-/-RRB-) ,/, (SBAR (WHNP-20 which/WDT) (S (NP-SBJ-21 *T*-20/-NONE-) (VP prevents/VBZ (NP (NP translocation/NN) (PP of/IN (NP ligated/VBN hGR/NN)) (PP to/TO (NP the/DT nucleus/NN))) (PP by/IN (S (NP-SBJ *-21/-NONE-) (VP inhibiting/VBG (NP (NP dissociation/NN) (PP of/IN (NP hGR/NN)) (PP from/IN (NP heat/NN shock/NN protein/NN 90/CD))))))))) ,/,) (ADVP completely/RB) (VP aborted/VBD (NP (NP the/DT effect/NN) (PP of/IN (NP dexamethasone/NN)) (PP on/IN (NP (NP adhesiveness/NN) (PP of/IN (NP (NP endothelial/JJ cells/NNS) (PRN -LRB-/-LRB- (S-COOD (S (NP-SBJ P/NN) (VP &lt;/VBG (NP 0.0005/CD))) ,/, (S (NP-SBJ n/NN) (VP =/JJ (NP-PRD 3/CD)))) -RRB-/-RRB-))))))) ./.)
(S (NP-SBJ (NP Treatment/NN) (PP of/IN (NP endothelial/JJ cells/NNS)) (PP with/IN (NP (NP LPS/NN) (PRN -LRB-/-LRB- (FRAG (NP 1/CD microgram\/ml/NN)) -RRB-/-RRB-)))) (VP-COOD (VP stimulated/VBD (NP-100 (NP transcription/NN) (PP of/IN (NP ELAM-1/NN))) ,/, (SBAR-101 as/IN (S (NP-SBJ-22 */-NONE-) (VP shown/VBN (NP *-22/-NONE-) (PP by/IN (NP Northern/NN blot/NN analysis/NN)))))) ,/, and/CC (VP (NP=100 (NP expression/NN) (PP of/IN (NP membrane-associated/JJ (NP-COOD (NP ELAM-1/NN) and/CC (NP ICAM-1/NN))))) ,/, (SBAR=101 as/IN (S (NP-SBJ-23 */-NONE-) (VP shown/VBN (NP *-23/-NONE-) (PP by/IN (NP (NP quantitative/JJ immunofluorescence/NN) (PRN -LRB-/-LRB- (S-COOD (S (NP-SBJ both/DT P/NN) (VP &lt;/VBG (NP 0.001/CD))) ,/, (S (NP-SBJ n/NN) (VP =/VBG (NP-PRD 9/CD)))) -RRB-/-RRB-)))))))) ./.)
(S (S (NP-SBJ Dexamethasone/NN) (ADVP markedly/RB) (VP inhibited/VBD (NP-COOD (NP (NP LPS-stimulated/JJ accumulation/NN) (PP of/IN (NP (NP mRNA/NN) (PP for/IN (NP ELAM-1/NN))))) and/CC (NP (NP expression/NN) (PP of/IN (NP (NP-COOD (NP ELAM-1/NN) and/CC (NP ICAM-1/NN)) (PRN -LRB-/-LRB- (S-COOD (S (NP-SBJ IC50/NN) (VP &lt;/VBG (NP 10/CD nM/NN))) ,/, (S (NP-SBJ both/DT P/NN) (VP &lt;/VBG (NP 0.001/CD))) ,/, (S (NP-SBJ n/NN) (VP =/VBG (NP-PRD 4-9/CD)))) -RRB-/-RRB-)))))) ;/:) (S (NP-SBJ-24 (NP inhibition/NN) (PP of/IN (NP expression/NN)) (PP by/IN (NP dexamethasone/NN))) (VP was/VBD (VP reversed/VBN (NP *-24/-NONE-) (PP by/IN (NP-LGS (NP RU-486/NN) (PRN -LRB-/-LRB- (S-COOD (S (NP-SBJ both/DT P/NN) (VP &lt;/VBG (NP 0.005/CD))) ,/, (S (NP-SBJ n/NN) (VP =/VBG (NP-PRD 4-6/CD)))) -RRB-/-RRB-))))) ./.))
(S (SBAR-ADV As/IN (FRAG (PP in/IN (NP the/DT adhesion/NN studies/NNS)))) ,/, (NP-SBJ-COOD (NP cortisol/NN) (CONJP but/CC not/RB) (NP tetrahydrocortisol/NN)) (VP inhibited/VBD (NP (NP expression/NN) (PP of/IN (NP (NP-COOD (NP ELAM-1/NN) and/CC (NP ICAM-1/NN)) (PRN -LRB-/-LRB- (S-COOD (S (NP-SBJ both/DT P/NN) (VP &lt;/VBG (NP 0.005/CD))) ,/, (S (NP-SBJ n/NN) (VP =/JJ (NP-PRD-COOD (NP 3/CD) or/CC (NP 4/CD))))) -RRB-/-RRB-))))) ./.)
(S (PP In/IN (NP contrast/NN)) ,/, (NP-SBJ (NP sodium/NN salicylate/NN) (PRN -LRB-/-LRB- (FRAG (NP 1/CD mM/NN)) -RRB-/-RRB-)) (VP inhibited/VBD (NP (NP-COOD neither/CC (NP adhesion/NN) nor/CC (NP expression/NN)) (PP of/IN (NP these/DT adhesion/NN molecules/NNS)))) ./.)
(S (NP-SBJ These/DT studies/NNS) (VP suggest/VBP (SBAR that/IN (S (NP-SBJ (NP antagonism/NN) (PP by/IN (NP dexamethasone/NN)) (PP of/IN (NP endotoxin-induced/JJ inflammation/NN))) (VP is/VBZ (NP-PRD (NP a/DT specific/JJ instance/NN) (PP of/IN (NP the/DT general/JJ biological/JJ principle/NN (SBAR that/IN (S (NP-SBJ the/DT glucocorticoid/NN receptor/NN) (VP is/VBZ (NP-PRD (NP a/DT hormone-dependent/JJ regulator/NN) (PP of/IN (NP transcription/NN))))))))))))) ./.)
